Uli C. Broedl
Binger Str. 173
Ingelheim Am Rhein, RP 55216, Germany
Ingelheim Am Rhein, RP 55216, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications
Framework of the strengths and challenges of clinically integrated trials: An expert panel report.
Journal: American heart journal
Published: May 13, 2024
Inclusion and diversity in clinical trials: Actionable steps to drive lasting change.
Journal: Contemporary clinical trials
Published: November 05, 2021
Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot.
Journal: Blockchain in healthcare today
Published: July 07, 2021
The role of machine learning in clinical research: transforming the future of evidence generation.
Journal: Trials
Published: April 30, 2021
Predictions for Blockchain in 2020.
Journal: Blockchain in healthcare today
Published: January 27, 2020
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Journal: Diabetes, obesity & metabolism
Published: December 11, 2019
Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: June 23, 2018
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
Journal: Journal of the American Society of Nephrology : JASN
Published: January 29, 2018
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
Journal: Cardiovascular diabetology
Published: January 13, 2018
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
Journal: Journal of the American Society of Hypertension : JASH
Published: April 19, 2017
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
Journal: Diabetologia
Published: April 05, 2017
Last Updated: 09/26/2026